Immune Design Corp. (NASDAQ:IMDZ)’s share price was up 3.7% during trading on Thursday . The company traded as high as $7.95 and last traded at $7.90, with a volume of 97,419 shares. The stock had previously closed at $7.62.

A number of equities analysts have commented on IMDZ shares. Zacks Investment Research lowered Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Leerink Swann reaffirmed a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a research note on Sunday, April 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $24.00.

The stock’s 50-day moving average is $8.22 and its 200 day moving average is $11.19. The stock’s market cap is $154.57 million.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.61) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.01. On average, equities research analysts forecast that Immune Design Corp. will post ($2.70) EPS for the current fiscal year.

A hedge fund recently raised its stake in Immune Design Corp. stock. Jennison Associates LLC increased its position in Immune Design Corp. (NASDAQ:IMDZ) by 0.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,452 shares of the company’s stock after buying an additional 769 shares during the period. Jennison Associates LLC owned 1.01% of Immune Design Corp. worth $4,085,000 at the end of the most recent quarter.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.